EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 295 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... June 19, 2023 Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... February 18, 2021 Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive... February 24, 2023 Load more HOT NEWS Five Questions With…Jessica, Katie, and Melanie New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in...
